| Re-challenge therapy with chemotherapy and panitumumab in metastatic colorectal cancer patients treated with an anti-EGFR therapy in 1st line treatment: a phase II multicentre study. |
Ongoing |
• PANITUMUMAB• OXALIPLATIN• irinotecan• FLOUROURACIL |
2 |
19-504 |
King Abdullah Medical City (Makkah) |
| "A multicenter, multinational, prospective, interventional,single-arm, Phase IV study evaluating the clinicalefficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin" |
Ongoing |
TOUJEO |
4 |
LPS15396 |
Sultan bin Abdulaziz Humanitarian city (Riyadh) |
| An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension |
Ongoing |
Interferon beta-1a |
3 |
105MS306 |
King Faisal Specialist Hospital and Research Center (Jeddah), King Khalid University Hospital (Riyadh) |
| A prospective Randomized study of General Anesthesia versus Anesthetist Administered sedation for ERCP |
Ongoing |
FENTANYL/ CISATRACURIUM/ SEVOFLURANE |
4 |
18-492 |
King Abdullah Medical City (Makkah) |
| "A multi-centre prospective non-interventional studyinvestigating the clinical effectiveness of Ryzodeg® (InsulinDegludec/Insulin Aspart) in patients with type 2 diabetesmellitus in a real-world setting" |
Ongoing |
Ryzodeg Flex Touch |
4 |
NN54014525 |
King Abdulaziz University Hospital (Jeddah), Ghassan Najeeb Pharaon hospital (Jeddah), Saudi German Hospital (Jeddah), Umm Al-Qura University (Makkah), Dallah Hospital (Riyadh), Riyadh Care Hospital (Riyadh), Specialized Medical Center (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis |
Ongoing |
Abatacept |
4 |
IM101240 |
King Abdulaziz Medical City NG (Riyadh) |
| CRAD001H2406- A long-term non-interventional observational study in Living Donor Liver Transplant Recipients (LDLTRs) with primary hepatocellular carcinoma (HCC) treated with Certican® / Zortress® (everolimus; EVR) plus reduced tacrolimus (rTAC) versus standard tacrolimus (sTAC) control |
Ongoing |
• everolimus • reduced tacrolimus |
4 |
CRAD001H24 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A multicenter, multinational, prospective, observational study to describe the clinical outcomes in patients with type 2 diabetes mellitus, treated with insulin glargine 300 U/mL (insulin glargine U300) before, during and after the period of Ramadan / ORION study |
Ongoing |
Toujeo |
4 |
OBS16040 |
King Abdulaziz University Hospital (Jeddah), Alzafer Hospital (Najran), University District Hospital (Jeddah), Saudi German Hospital (Jeddah) |
| A prospective, multicenter, observational study to evaluate patients’ quality oflife in routine clinical practice in patients with relapsing-remitting multiplesclerosis (RRMS) treated with LEMTRADA® |
Ongoing |
alemtuzumab |
4 |
OBS15590 |
Al-Noor Specialist Hospital (Makkah), King Khalid University Hospital (Riyadh), King Saud Medical City (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah) |
| An observational prospective study of switching asthma patients from a fixed-dose combination (FDC) Inhaled Corticosteroids [ICS] / Long-Acting Beta-Agonists [LABA] therapy delivered by pMDI Seretide® Evohaler to ICS/LABA delivered by pMDI Flutiform® |
Ongoing |
Flutiform |
4 |
FLT18-KSA |
King Fahad Medical City (Riyadh), Prince Sultan Military Medical City (Riyadh) |
